tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Jul 18;24(1):705.
doi: 10.1186/s12879-024-09615-3. Pediatric antibody responses to SARS-CoV-2 after infection and vaccination in Calgary, Canada
Leah J Ricketson[SUP] 1 [/SUP], Emily J Doucette[SUP] 1 [/SUP], Isabella Alatorre[SUP] 1 [/SUP], Tarannum Tarannum[SUP] 1 [/SUP], Joslyn Gray[SUP] 1 [/SUP], William Booth[SUP] 1 [/SUP], Graham Tipples[SUP] 2 3 4 5 [/SUP], Carmen Charlton[SUP] 2 3 6 [/SUP], Jamil N Kanji[SUP] 2 6 7 8 [/SUP], Kevin Fonseca[SUP] 2 8 [/SUP], James D Kellner[SUP] 9 10 [/SUP]
Affiliations
Background: There are few reports of longitudinal serologic responses in children following Sars-CoV-2 infection and vaccination. This study describes longitudinal SARS-CoV-2 antibody responses following infection, vaccination, or both (hybrid immunity) in a cohort of Canadian children. The objectives of our study were to compare antibody levels following SARS-CoV-2 infection, vaccination, and hybrid immunity and to examine antibody decline after final antigen exposure.
Methods: The Alberta Childhood COVID-19 Cohort (AB3C) study was a prospective longitudinal cohort study conducted from July 2020 to September 2022 with repeat sampling across 5 visits. Children under 18 years of age were enrolled for serial measurement of antibody responses to SARS-CoV-2 virus vaccine and infection.
Results: The final sample size was 919; participants were 50.5% female, 48.2% were > 12 years and 88.5% were white ethnicity. The median peak spike IgG level of those with only infection was not different from those with no vaccination or infection (233 AU/mL (IQR: 99-944 AU/mL) vs. 3 AU/mL (IQR: 1-5 AU/mL; P = 0.1765). Participants with infections after vaccination had higher IgG levels than those where infection preceded vaccination (median: 36,660 (IQR: 22,084 - 40,000 AU/mL) vs. 17,461 AU/mL (IQR: 10,617 - 33,212 AU/mL); P < 0.0001). In a linear mixed methods model, children with infection-only had low levels of antibody that stayed stable over the study duration without further antigen exposures. Those with infection after vaccination had the slowest rate of antibody decline over time at 4% (95%CI: 2-5%) per week, compared with children where infection preceded vaccine 7% (95%CI: 6-8%) per week.
Conclusions: Children with hybrid immunity conferred through vaccination (2 + doses) followed by a SARS-CoV-2 infection had the highest and longest lasting antibody levels, compared to children who had an infection followed by vaccination, vaccination-only, or infection-only. The longer-term clinical importance of these findings, related to prevention of repeated infections and severe outcomes and need for further vaccine doses, is not yet known.
Keywords: COVID-19; Hybrid immunity; Pediatrics; SARS-CoV-2; SARS-CoV-2 immunity.
. 2024 Jul 18;24(1):705.
doi: 10.1186/s12879-024-09615-3. Pediatric antibody responses to SARS-CoV-2 after infection and vaccination in Calgary, Canada
Leah J Ricketson[SUP] 1 [/SUP], Emily J Doucette[SUP] 1 [/SUP], Isabella Alatorre[SUP] 1 [/SUP], Tarannum Tarannum[SUP] 1 [/SUP], Joslyn Gray[SUP] 1 [/SUP], William Booth[SUP] 1 [/SUP], Graham Tipples[SUP] 2 3 4 5 [/SUP], Carmen Charlton[SUP] 2 3 6 [/SUP], Jamil N Kanji[SUP] 2 6 7 8 [/SUP], Kevin Fonseca[SUP] 2 8 [/SUP], James D Kellner[SUP] 9 10 [/SUP]
Affiliations
- PMID: 39026179
- DOI: 10.1186/s12879-024-09615-3
Background: There are few reports of longitudinal serologic responses in children following Sars-CoV-2 infection and vaccination. This study describes longitudinal SARS-CoV-2 antibody responses following infection, vaccination, or both (hybrid immunity) in a cohort of Canadian children. The objectives of our study were to compare antibody levels following SARS-CoV-2 infection, vaccination, and hybrid immunity and to examine antibody decline after final antigen exposure.
Methods: The Alberta Childhood COVID-19 Cohort (AB3C) study was a prospective longitudinal cohort study conducted from July 2020 to September 2022 with repeat sampling across 5 visits. Children under 18 years of age were enrolled for serial measurement of antibody responses to SARS-CoV-2 virus vaccine and infection.
Results: The final sample size was 919; participants were 50.5% female, 48.2% were > 12 years and 88.5% were white ethnicity. The median peak spike IgG level of those with only infection was not different from those with no vaccination or infection (233 AU/mL (IQR: 99-944 AU/mL) vs. 3 AU/mL (IQR: 1-5 AU/mL; P = 0.1765). Participants with infections after vaccination had higher IgG levels than those where infection preceded vaccination (median: 36,660 (IQR: 22,084 - 40,000 AU/mL) vs. 17,461 AU/mL (IQR: 10,617 - 33,212 AU/mL); P < 0.0001). In a linear mixed methods model, children with infection-only had low levels of antibody that stayed stable over the study duration without further antigen exposures. Those with infection after vaccination had the slowest rate of antibody decline over time at 4% (95%CI: 2-5%) per week, compared with children where infection preceded vaccine 7% (95%CI: 6-8%) per week.
Conclusions: Children with hybrid immunity conferred through vaccination (2 + doses) followed by a SARS-CoV-2 infection had the highest and longest lasting antibody levels, compared to children who had an infection followed by vaccination, vaccination-only, or infection-only. The longer-term clinical importance of these findings, related to prevention of repeated infections and severe outcomes and need for further vaccine doses, is not yet known.
Keywords: COVID-19; Hybrid immunity; Pediatrics; SARS-CoV-2; SARS-CoV-2 immunity.